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Background: Hypoglycaemic events, particularly nocturnal, affect health-related quality of life (HRQoL) via acute
symptoms, altered behaviour and fear of future events. We examined the respective disutility associated with a
single event of daytime, nocturnal, severe and non-severe hypoglycaemia.
Methods: Representative samples were taken from Canada, Germany, Sweden, the United States and the United
Kingdom. Individuals completed an internet-based questionnaire designed to quantify the HRQoL associated with
different diabetes- and/or hypoglycaemia-related health states. HRQoL was measured on a utility scale: 1 (perfect
health) to 0 (death) using the time trade-off method. Three populations were studied: 8286 respondents from the
general population; 551 people with type 1 diabetes; and 1603 with type 2 diabetes. Respondents traded life
expectancy for improved health states and evaluated the health states of well-controlled diabetes and diabetes
with non-severe/severe and daytime/nocturnal hypoglycaemic events.
Results: In the general population, non-severe nocturnal hypoglycaemic events were associated with a 0.007
disutility compared with 0.004 for non-severe daytime episodes, equivalent to a significant 63% increase in negative
impact. Severe daytime and nocturnal events were associated with a 0.057 and a 0.062 disutility, respectively, which
were not significantly different.
Conclusions: This study applies an established health economic methodology to derive disutilities associated with
hypoglycaemia stratified by onset time and severity using a large multinational population. It reveals substantial
individual and cumulative detrimental effects of hypoglycaemic events – particularly nocturnal – on HRQoL,
reinforcing the clinical imperative of avoiding hypoglycaemia.
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Hypoglycaemia is defined as a deficiency of glucose in
the bloodstream causing neuroglycopenic and auto-
nomic symptoms, and is a well-recognized side effect in
the insulin-based management of both type 1 and type 2
diabetes, with a reported overall incidence of 42.9 events
per patient-year for type 1 diabetes and 16.4 events per
patient-year for type 2 diabetes [1]. Biochemical defini-
tions for low plasma glucose range between 3.0 mmol/L* Correspondence: marc.evans2@ntlworld.com
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reproduction in any medium, provided the or(European Medicines Agency) and 3.9–4.0 mmol/L
(American Diabetes Association and Canadian Diabetes
Association, respectively) [2-4]. Clinically, events can be
subdivided into non-severe events, for which the indivi-
dual is able to take remedial action, and severe events,
for which third-party assistance is required. Episodes of
hypoglycaemia may occur during the day (diurnally) or
nocturnally, with the latter being particularly unpredic-
table. Hypoglycaemia symptoms often include, but are
not limited to, trembling, hunger, sweating, difficulty
concentrating, confusion, unconsciousness, or coma,
and, in rare cases, death [5]. The debilitating effects of
severe hypoglycaemia are widely acknowledged, buttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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turnal events on patient wellbeing [6,7]. Hypoglycaemia
can impact patient health-related quality of life (HRQoL)
in two ways: firstly, through the direct physiological
effects of repeated episodes; and secondly, through fear
of future hypoglycaemia, leading to the adoption of
avoidant, precautionary or compensatory actions (e.g.,
restricting holiday choices, avoiding physical exertion,
defensive eating, insufficient insulin dosing) [7-10].
Moreover, repeated events can lead to impaired hypo-
glycaemia awareness, a condition affecting 20–25% of
patients with type 1 diabetes and up to 10% of patients
with type 2 diabetes, which raises the risk of severe
hypoglycaemia and associated morbidity by up to six-
fold [11].
To determine the HRQoL impact of hypoglycaemia,
the impact per event must be quantified, which can be
achieved by determining a ‘health utility’. Utilities enable
HRQoL to be placed on a scale where a value of 1
corresponds to perfect health and 0 to death [12,13].
Although studies describing utility values for diabetes-
related hypoglycaemic events exist, participant numbers
have been generally small and the methods employed
have suffered from various limitations; for example, a
failure to estimate utility per event or to determine the
impact of onset time or severity [14-18]. It is clear,
therefore, that a significant knowledge gap remains
regarding the relative utilities associated with a non-
severe compared with a severe hypoglycaemic event, and
how the timing of onset may further affect HRQoL.
The primary purpose of this study was to elicit a set of
utility values for hypoglycaemic events using time trade-
off (TTO) methods that can be used to assess the overall
patient benefits of using appropriate diabetes medi-
cation. These utility values could be used directly as an
input to diabetes decision models, and under certain
assumptions can be used to estimate quality-adjusted
life-years (QALYs) [19,20]. For example, in a guide to
technology appraisal methods, the UK National Institute
for Health and Clinical Excellence (NICE) advocates
direct health-state valuations determined using the TTO
method in a representative population sample in situa-
tions where EQ-5D™ data are unavailable [21].
The secondary objective was to examine the relative ef-
fects of diurnal and nocturnal hypoglycaemia on HRQoL,
based on the hypothesis that nocturnal hypoglycaemic
events, irrespective of severity, may have more impact
than diurnal events due to their unpredictability.
Methodology
Time trade-off (TTO) methodology
Utility values are obtained by asking respondents to ‘trade
off ’ a portion of their remaining lifespan for an improved
health state [19,22-29]. For example, respondents mightchoose between two options: A – to live in full health for
27 years and 0 months; or B – to have diabetes, experience
non-severe daytime hypoglycaemia once a month, and live
for 30 years and 0 months. If the respondent chooses
option A, they are willing to exchange remaining lifetime
(i.e., 3 years) to avoid living with diabetes and non-severe
hypoglycaemia once a month, thereby indicating their uti-
lity in this health state is less than 0.9 (=27 years/30 years).
Conversely, if they choose B, they indicate that their utility
in this health state is more than 0.9. To make the trade-
offs as realistic as possible, the time horizons used were
based on each respondent’s projected life expectancy,
obtained using the country, age and sex of the respondent
at the time of the study, and the most recent World
Health Organization life tables [30]. In order to test
respondents’ understanding of the TTO concept, a test
question was included offering a choice of full health and
a longer remaining lifetime, or less than full health and a
reduced lifetime. Respondents choosing the second option
were excluded from analysis.
To identify the point of indifference (where both
options are equally acceptable), respondents were asked
the question repeatedly, varying only the number of
years living in full health each time. This procedure
followed standard bisection methodology, using a star-
ting point of utility = 0.6 to reduce the utility value to an
interval of 0.05.
Particular attention was given to the distribution tails.
Respondents who either chose not to trade lifetime at a
utility value of 0.95, or who were willing to trade a very
high proportion of their remaining lifetime (0.875) to be
restored to full health, were both carefully screened.
Responses were excluded if the respondents refused to
trade on ethical or religious grounds, or if they did not
understand the question. However, those who believed
the health state manageable or who stated a desire to
live as long as possible due to obligations (e.g., care-
givers) were retained.Definition of health states
The descriptions of hypoglycaemia health states were
derived from a survey of 247 UK patients with diabetes.
The survey was initially developed based on expert opi-
nion garnered through an advisory board (which included
all authors). The patients validated symptom descriptions
for a non-severe daytime hypoglycaemic event, a non-
severe nocturnal hypoglycaemic event and a severe hypo-
glycaemic event. In addition, they stated the level to which
having hypoglycaemic events affected the frequency of
certain diabetes-related and hypoglycaemia-related actions
and worries in their daily lives. Together, this led to the
definition of the 13 health states describing diabetes alone
or diabetes combined with hypoglycaemia of differing
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Survey description and methodology
Data were collected through an internet-based survey
using an existing panel of prospective participants, an
approach previously used successfully by other groups
[31-33]. The panel covered a representative sample of
the general populations in Canada, Germany, Sweden,
the United States (US) and the UK. There remains a
debate in the literature as to whether patient or public
preferences carry the most influence when determining
the value attached to a particular health state [34-36].
Therefore, to determine whether responses differed bet-
ween the general population and people who may have
personal experience of hypoglycaemia, a second popula-
tion with type 1 diabetes and a third population with
type 2 diabetes were also identified from the available
panel. The study was carried out in accordance with the
European Pharmaceutical Market Research Association
code of conduct. Ethical approval was obtained from the
University of Western Ontario Health Sciences Research
Ethics Board in Canada (review number 181676) and
Regionala Etikprövningsnåmnden, Lund, Sweden, where
appropriate. All those contacted had previously agreed
to participate in internet-based surveys. Various chan-
nels including web banners, telephone interviews and
personal interviews were used for recruitment to ensure
it remained representative. Only people aged 18 years or
older were approached and took part at their discretion,
and respondent anonymity was preserved throughout.
Depending on the country, respondents were offered
‘points’ for online shopping or entry in a draw (nominal
value 1–2 euros) as incentives to participate. The ques-
tionnaire was programmed in a commercial survey
software package. To improve the answer quality and
prevent unconsidered responses, a 10-second delay was
introduced to pages containing a large amount of text.
The survey was carried out in Swedish (Sweden),
German (Germany), English (Canada, UK, and US) and
French (Canada). Canadian respondents could choose
between a French- or an English-language version. The
questionnaire was translated into the respective language
and back to English to ensure the veracity of each
translation.
The functionality of the questionnaire was validated in
a pilot study of 200 respondents. Following this, a few
minor adjustments were made, including the addition of
extra background questions and a question for screening
respondents trading a very high proportion of their
remaining life expectancy, and slight wording alterations
to increase clarity.
Respondents were excluded based on the following
criteria:A. Those who failed a test question.
B. Inconsistency: those who valued the health state of
baseline diabetes (i.e., without hypoglycaemia or
other complications) worse than all three of the
following health states:
 Diabetes and non-severe daytime hypoglycaemic
events
 Diabetes and non-severe nocturnal
hypoglycaemic events
 Diabetes and severe hypoglycaemic events.
In order to avoid respondent fatigue, individuals did
not evaluate all 13 health states but were randomly
assigned to:
 One health state of well-controlled diabetes
 One health state with non-severe daytime
hypoglycaemia
 One health state with non-severe nocturnal
hypoglycaemia
 One health state with severe hypoglycaemia (day or
night).
In addition, respondents were required to provide
their age and sex; to answer socioeconomic questions re-
garding their employment, household and region; and to
complete an EQ-5D™ survey. Respondents with diabetes
were asked to provide further information regarding the
duration of diabetes, current medication, prevalence of
hypoglycaemic events, awareness of hypoglycaemic
events and current HbA1c value or 7-day average blood
sugar level. In the general population group, 1.8% and
8.7% of respondents had type 1 diabetes and type 2
diabetes, respectively.Statistical analysis
All statistical analyses were performed using SAS® version
9.2 statistical software. A utility value was assigned to each
health state based on each individual response, derived
from the midpoint of the indifference interval derived as
described above. The average utility value was calculated
for each health state, and a disutility per hypoglycaemic
event derived by dividing the difference between the ave-
rage utility and the baseline diabetes state utility by the
number of annual events, to ensure that the resulting
value reflected the effect of hypoglycaemia alone.
For each hypoglycaemic event class, up to four differ-
ent event frequencies (health states) were evaluated
(Additional file 2: Table S2). Unit values per hypogly-
caemic incident type were calculated from the average
TTO value for each frequency, weighted according to
the distribution of those specific hypoglycaemic event
frequencies among the participants with diabetes.







N (%) N (%) N (%)
Gender
Male 4237 (51) 308 (56) 898 (56)
Female 4049 (49) 243 (44) 705 (44)
Mean age (±SD) 46 ±16 39 ±14 54 ±12
Mean EQ-5D™ score (±SD) 0.81 ±0.25 0.72 ±0.30 0.70 ±0.31
Occupation
In full-time education 550 (7) 58 (11) 44 (3)




444 (5) 10 (2) 28 (2)
Permanently unable to
work due to long-term
sickness/disability
595 (7) 29 (5) 72 (4)
Retired 1430 (17) 70 (13) 249 (16)
Looking after home or family 816 (10) 49 (9) 496 (31)
Other 539 (7) 47 (9) 135 (8)
Household status
1 adult, no children 1761 (21) 126 (23) 373 (23)
1 adult, children 430 (5) 33 (6) 65 (4)
2 adults, no children 3060 (37) 166 (30) 729 (45)
2 adults, children 2042 (25) 152 (28) 263 (16)
3 adults, no children 482 (6) 31 (6) 81 (5)
3 adults, children 201 (2) 23 (4) 43 (3)
Other 310 (4) 20 (4) 49 (3)
Total 8286 (100) 551 (100) 1603 (100)
SD, standard deviation.
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populations contain combined data from any general
population respondents with type 1 or type 2 diabetes
and data from the respective type 1 or type 2 diabetes
populations.
As the response distribution was unknown but sus-
pected to be non-normal, non-parametric bootstrapping
was used to simulate standard errors and confidence
intervals (CIs) for the mean TTO values. This method
estimates the parameter’s distribution by repeatedly
resampling the original data set with replacement
[37-39]. For the present study, 10,000 iterations were
performed.
Because it is rare for a patient with diabetes to experi-
ence severe hypoglycaemic events without non-severe
events, some of the worries and limits to daily activities
may already be accounted for by the disutility associated
with non-severe events. Therefore, the initial disutility
value (determined as the intercept in a regression model)
for non-severe hypoglycaemic events was subtracted from
the value obtained for severe hypoglycaemic events.
Results
Study population
Of the original 11,196 general population respondents
who started the questionnaire, 10,087 (90%) completed
it. A further 1178 respondents (10.5%) were excluded for
failing the test question and 623 (6%) were excluded due
to inconsistencies. The final general population sample
was based on 8286 respondents, constituting 82% of the
initial total, spread across five countries (1696 from
Canada, 1607 from Germany, 1635 from Sweden, 1675
from the UK and 1673 from the US). The diabetes popu-
lations comprised 551 people with type 1 and 1603 with
type 2. Table 1 summarizes background characteristics
for each population.
Time trade-off results
For the baseline diabetes health state, 22% of the general
population respondents (19–21% for the other health
states) chose either not to trade or to trade all, placing
them at the distribution extremes. Of these, 8% (8–11%
for the other health states) were excluded from analysis
according to the predefined criteria. Similar magnitudes
of exclusion were seen in the diabetes populations.
The average TTO utility values for each health state
are shown in Table 2 and Additional file 3: Figure S1.
The utility value for well-controlled baseline diabetes
was 0.844. Respondents considered living in a health
state with severe or non-severe nocturnal hypoglycaemia
worse than living in a health state with severe or non-
severe daytime hypoglycaemia, irrespective of event
frequency (Table 2). Similarly, they considered a health
state with severe hypoglycaemia worse than a healthstate with an equivalent frequency of non-severe
hypoglycaemia (for ‘one quarterly’, daytime, the values
were 0.739 and 0.812 respectively).
In general, as the frequency of hypoglycaemia in-
creased, the utility value decreased, with the exception
of non-severe daytime hypoglycaemia, where a frequency
of one event quarterly resulted in the same utility as one
event monthly (Table 2).
Table 3 shows the estimated average disutility associ-
ated with an annual hypoglycaemic event for the general
population overall or stratified by country, and for the
populations with either type 1 or type 2 diabetes.
Looking at the total population, a non-severe noctur-
nal hypoglycaemic event was associated with a disutility
that was decreased by 0.003 (that is, from 0.007 to 0.004
[95% CI 0.002 to 0.003]) compared with non-severe
daytime hypoglycaemia, equivalent to a significant 63.4%
increase in negative impact (Figure 1). Severe nocturnal
hypoglycaemia was associated with a disutility decrease
Table 2 Average time trade-off utility values for health states [95% CIs, bootstrapped]
Frequency of hypoglycaemic events
Health state One a year One a quarter One a month One a week Three a week
Baseline diabetes 0.844
[0.839 to 0.848]
– – – – –












0.775 [0.764 to 0.786] 0.729
[0.717 to 0.740]










Total for all countries, general population.
CI, confidence interval.
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0.0114]) compared with severe daytime hypoglycaemia,
which was not statistically significant (Additional file 4:
Figure S2).
When country-specific disutility values were compared
with the overall values (Table 3), participants from
Germany reported significantly lower disutilities (0.002
[95% CI 0.001 to 0.003] compared with 0.004 [95% CI
0.004 to 0.005] overall) for non-severe daytime hypo-
glycaemia (p = 0.00098) and non-severe nocturnal hypo-
glycaemia (0.004 [95% CI 0.003 to 0.006] compared with
0.007 [95% CI 0.006 to 0.007]; p = 0.0027). Similarly,
Swedish participants also produced significantly lower
disutilities for non-severe daytime hypoglycaemia (0.003
[95% CI 0.001 to 0.004] compared with 0.004 [95% CI
0.004 to 0.005] overall; p = 0.049) and severe daytime
hypoglycaemia (0.047 [95% CI 0.038 to 0.055] compared
with 0.057 [95% CI 0.053 to 0.061]; p = 0.032). In con-
trast, Canadian participants reported a significantly
higher disutility for non-severe daytime hypoglycaemia
(0.006 [95% CI 0.004 to 0.007] compared with 0.004
[95% CI 0.004 to 0.005] overall; p = 0.047). No country-Table 3 Disutility per hypoglycaemic event per year [95% CIs
Non-severe daytime event Non-severe noctu
General population
Total 0.004 [0.004 to 0.005] 0.007 [0.006 to
Canada 0.006 [0.004 to 0.007] 0.008 [0.006 to
Germany 0.002 [0.001 to 0.003] 0.004 [0.003 to
Sweden 0.003 [0.001 to 0.004] 0.007 [0.005 to
UK 0.005 [0.004 to 0.007] 0.008 [0.060 to
US 0.005 [0.004 to 0.006] 0.007 [0.005 to
Populations with diabetes
Type 1 diabetes 0.004 [0.001 to 0.006] 0.008 [0.005 to
Type 2 diabetes 0.005 [0.003 to 0.006] 0.007 [0.005 to
CI, confidence interval.specific significant differences in severe nocturnal hypo-
glycaemia disutilities were reported.
Overall, the disutilities obtained from the populations
with type 1 or type 2 diabetes were similar to those of
the general population. However, the type 2 diabetes
population reported a significantly higher disutility for
severe nocturnal hypoglycaemia (p = 0.008) compared
with the general population (Additional file 5: Figure S3
and Additional file 6: Figure S4).
Correction of the initial disutility value for severe
hypoglycaemic events resulted in an average reduction
in the unit value for severe disutilities of 0.02 (ranging
between 0.01 for Germany and 0.03 for UK; data not
shown). However, this correction did not significantly
affect the main findings.
Discussion
The TTO method is a standard tool in the health
economics evaluation arsenal, advocated for direct
health-state valuations by health-technology assessment
bodies. This study used a web-based TTO survey to
determine the relative effects of severe, non-severe,, bootstrapped]
rnal event Severe daytime event Severe nocturnal event
0.007] 0.057 [0.053 to 0.061] 0.062 [0.058 to 0.066]
0.009] 0.059 [0.050 to 0.069] 0.062 [0.052 to 0.071]
0.006] 0.060 [0.052 to 0.068] 0.066 [0.057 to 0.075]
0.008] 0.047 [0.038 to 0.055] 0.060 [0.052 to 0.069]
0.010] 0.062 [0.054 to 0.071] 0.066 [0.057 to 0.076]
0.009] 0.055 [0.046 to 0.065] 0.057 [0.048 to 0.067]
0.011] 0.047 [0.033 to 0.062] 0.051 [0.037 to 0.065]
0.010] 0.060 [0.051 to 0.069] 0.078 [0.067 to 0.089]
Figure 1 Disutility associated with yearly incidence of non-
severe daytime and nocturnal hypoglycaemic effects.
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and, as such, is the first analysis to provide a quantitative
disutility value for each event class, and to demonstrate
a clear increase in disutility for nocturnal compared with
diurnal hypoglycaemic events.
As would be predicted based on clinical and patient-
reported experiences, increasing event severity is associated
with greater disutility. There were some variations between
countries, with significantly lower disutilities reported for
Germany and Sweden, and a significantly higher value
reported for Canada for non-severe hypoglycaemia com-
pared with the overall population. However, it is perhaps
most interesting to note the high overall similarity between
populations. The response consistency observed both
across populations and between countries supports the
credibility of the results and suggests that hypoglycaemia-
related disutility is comparable and independent of health-
care system differences.
This study sampled a large number of respondents
from multiple countries, 78–81% of whom were willing
to trade-off health improvements against projected life
expectancy, indicating understanding and acceptance of
the TTO concept. The respondents represented three
distinct groups: the general population, people with type
1 diabetes and people with type 2 diabetes, providing a
unique opportunity to identify any significant diffe-
rences. Indeed, a significantly higher disutility for severe
nocturnal hypoglycaemia was reported by the type 2
diabetes population (p = 0.008).
The web-based approach, whilst facilitating respon-
dent participation, does mean that help was not available
if respondents had queries. Additionally, although a time
delay was built into the survey, the lack of supervision
may have led to some respondents not spending enough
time considering their answers. Collectively, these design
attributes may have led to inconsistencies within the
responses. It should be noted, however, that the low
dropout rate (10%) indicates the questionnaire was clearand manageable for most respondents, and potential
skewing due to respondent fatigue was minimized by the
methods employed.
Although participation bias must be considered, the
incentives to participate would be expected to mitigate
any initial disinclination. A recent report suggests that
the application of discounting to correct for time prefer-
ences has an influential effect on outcomes [40]; we did
not apply this in the present study. The use of an internet-
based survey may also pose a selection bias, since only
literate respondents with computer access could partici-
pate. However, the literacy rates and proportion of inter-
net users in all sampled countries are high (e.g., the UK
has a 99% literacy rate and 51.1 million computer users
out of 63 million inhabitants) [41].
A further strength of this study is that the findings are
of a similar magnitude compared with previous research.
The observed baseline diabetes utility value of 0.844
found in the current study is in line with that reported
previously [18]. A recent review found every non-severe
event (day and night) may be associated with a utility
loss of between 0.0033–0.0052 over 1 year [42]. How-
ever, previous studies describing diabetes-related utility
values for hypoglycaemic events have various limitations.
Cross-sectional studies using generic health instruments
either suffer from potential unobserved confounding or
do not estimate utility per event [14-16]. Matza and
colleagues studied 129 people with type 2 diabetes, using
the standard gamble technique, and found a significant
disutility (p < 0.001) associated with the fear of hypogly-
caemia overall, but did not distinguish between onset
time or severity, or calculate disutility per event [17]. In
contrast, Levy and colleagues surveyed 51 people with
diabetes and 154 respondents without diabetes, using a
TTO approach to estimate utility values per hypogly-
caemic event, but did not report values for nocturnal or
severe events [18]. In addition, these previous studies
were limited by small sample sizes.
Moreover, the use of age-dependent, life-expectancy-
based adaptation of the TTO questions for each res-
pondent, applied successfully by other groups [32,33],
may avoid some of the disadvantages of the artificial
fixed 10- or 30-year horizon used elsewhere [18,22] by
increasing the relevance of the trade-offs to the res-
pondents and so providing more reliable utility value
estimates.
Non-severe hypoglycaemic events have been shown to
have a measurable detrimental impact on patient well-
being, reflected by increased healthcare professional
visits (25% of participants) and higher testing-strip
consumption (5.6 on average), and a quarter of respon-
dents reduced their insulin dose in the days immediately
following an event [7]. After a non-severe nocturnal
event, 23% of respondents reported arriving late or
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deadline [7]. Although an association between nocturnal
hypoglycaemia and reduced HRQoL was demonstrated,
the current investigation is the first analysis to provide
quantitative disutility values and to demonstrate a clear
increase in disutility for nocturnal compared with diur-
nal hypoglycaemic events.
Within clinical practice there is recognition of the
phenomenon of ‘first being worst’; that is, the effect of
each hypoglycaemic event on HRQoL diminishes as
frequency increases and the patient adapts. In health
economic terms, this is referred to as diminishing
marginal disutility. Interestingly, the degree of disutility
associated with increasing frequency of non-severe
hypoglycaemic events consistently increased in this study,
irrespective of onset time. The diminishing marginal
disutility may reflect a coping mechanism, a maximum
trade-off limit, or study design limitations, where some
respondents might pay more attention to the health-state
descriptions than the actual frequencies.
Identifying a minimally important difference (MID),
described as the smallest change in the patient-reported
outcome of interest that is either perceived as beneficial
or that would elicit a change in behaviour [43,44],
underpins the clinical relevance interpretation of any
HRQoL study. However, no universally accepted method
for MID estimation exists, with both anchor-based or
distribution-based methods being employed [45-47]. An
MID has been reported for some generic health instru-
ments; Drummond reported an MID in utilities of 0.03
for the 15D instrument and the Health Utilities Index
(HUI®), with the elaboration that utilities of 0.01 may be
meaningful in some contexts [48]. Luo and colleagues
reported mean MID estimates of 0.040 for the EQ-5D™
(US algorithm), 0.082 for the EQ-5D™ (UK algorithm),
0.045 for the HUI-2, 0.032 for the HUI-3 and 0.027 for
the SF-6D [45]. Generic instruments generally lack sen-
sitivity, which is why direct elicitation using an approach
such as TTO becomes relevant. When patients trade a
portion of their life expectancy to improve quality of life,
they implicitly express the importance of the health
state. In this study, the utility differences derived are per
event; therefore, whilst they appear small initially, when
the predicted annual event frequency is considered, the
differences would be quite substantial.Conclusion
In summary, this analysis provides a unique evaluation
of severe compared with non-severe hypoglycaemic
events, and of the distinction between daytime and
nocturnal hypoglycaemia, providing a comprehensive
breakdown of the respective contributions made by each
of these distinct event subgroups to patient HRQoL.Ethical approval
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